Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Cosentyx (secukinumab) for Treatment of Plaque Psoriasis

Drug (Brand/Generic)

Cosentyx (secukinumab)

Company/Licensee

Novartis International

Product Description

Human monoclonal antibody

Current Indication

Moderate-to-severe plaque psoriasis

Market Sector

Dermatology

Development Status

Approved in the US, EU, Australia and Japan
Expand
Close
Close
Close

Go Top